RIVANNA Fast-Tracks AI Fracture Detection With BARDA-Backed Multi-Site Study Expansion

New updates have been reported about RIVANNA.

RIVANNA has sharply accelerated development of its Accuro XV musculoskeletal imaging platform by expanding its AI-focused clinical study from two to eight U.S. sites, following the exercise of a funding option by BARDA under ASPR at HHS. With 10 systems now deployed and all sites enrolling, the company expects this broader dataset to compress its FDA 510(k) submission timeline for AI-enabled fracture detection, a key step in its diagnostic roadmap.

The study is designed to build a large, multi-center 3D imaging database of upper and lower extremity injuries to train RIVANNA’s CADe/x automated fracture detection algorithm and finalize validation of BoneEnhance, its bone visualization and segmentation module. Early data from 666 enrolled patients indicate Accuro XV imaging is associated with significantly less increase in pain versus X-ray among patients who did not receive analgesia, suggesting potential patient-experience benefits that complement the platform’s clinical and workflow value.

Renowned emergency medicine investigators at major academic and safety-net institutions are leading the study, reinforcing RIVANNA’s strategy of anchoring product validation in high-volume, complex care settings. Executives highlight that scaling from two to eight sites in four months demonstrates the firm’s operational agility and depth of relationships with academic medical centers, assets that could support faster adoption if the technology secures clearance.

Accuro XV combines a portable, volumetric ultrasound system with AI-driven software aimed at delivering a fracture-care layer at triage, helping emergency departments streamline evaluation of low-severity extremity injuries and reduce reliance on X-ray referrals. If successfully cleared, the integrated BoneEnhance and CADe/x modules could position RIVANNA to capture share in fracture care and emergency preparedness markets, leveraging an IP portfolio of more than 100 patents and an FDA-registered, ISO 13485-certified manufacturing base in Charlottesville.